Literature DB >> 29633867

An update on adverse drug reactions related to β-lactam antibiotics.

Konstantinos Z Vardakas1,2, Georgios D Kalimeris1,2, Nikolaos A Triarides1,2, Matthew E Falagas1,2,3.   

Abstract

INTRODUCTION: β-lactams have been consistently associated with the majority of drug-related adverse events. Generally, these are mild under proper dosing and judicious selection. AREAS COVERED: Immediate hypersensitivity reactions are the most feared adverse events encountered after β-lactam administration. Emerging evidence shows that immediate reactions are not as common as previously thought. Specialist consultation and testing seems prudent before a patient is officially declared allergic to β-lactams. The risk of cross-reactions between not only members of the β-lactam super-family but also between specific classes is also lower than previously thought. Newer studies have shown that cross-reactions are not universal and pertain to specific agents with similar side chains or metabolites of the β-lactam core. The frequency of severe kidney or liver toxicity, neurotoxicity, cytopenias and Clostiridium difficile infection following β-lactam administration seem to be agent-specific. EXPERT OPINION: The currently available data denote that in addition to age, gender, co-morbidity, renal or liver function, and co-administered agents, the antibiotic levels rather than the dose itself seem to be associated with the emergence of adverse events. Most of them subside with time after withdrawal of the offending agent, but the number of cases resulting in chronic disabilities or even deaths in not negligible.

Entities:  

Keywords:  Aztreonam; adverse drug reactions; beta lactam allergy; beta lactams; carbapenem; cephalosporin; cytopenia; hepatotoxicity; nephrotoxicity; penicillin

Mesh:

Substances:

Year:  2018        PMID: 29633867     DOI: 10.1080/14740338.2018.1462334

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  9 in total

1.  Antibiotic prophylaxis with high-dose cefoxitin in bariatric surgery: an observational prospective single center study.

Authors:  Thibaut Belveyre; Philippe Guerci; Elise Pape; Nathalie Thilly; Kossar Hosseini; Laurent Brunaud; Nicolas Gambier; Claude Meistelman; Marie-Reine Losser; Julien Birckener; Julien Scala-Bertola; Emmanuel Novy
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

2.  Safety of Antibiotics in Hospitalized Children in Romania: A Prospective Observational Study.

Authors:  Noémi-Beátrix Bulik; Andreea Farcaș; Camelia Bucșa; Irina Iaru; Ovidiu Oniga
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-03

3.  Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.

Authors:  Thomas M File; Elizabeth Alexander; Lisa Goldberg; Anita F Das; Christian Sandrock; Susanne Paukner; Gregory J Moran
Journal:  BMC Pulm Med       Date:  2021-05-08       Impact factor: 3.317

4.  Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the 'Maximum Tolerable Dose'.

Authors:  Sofie A M Dhaese; Eric A Hoste; Jan J De Waele
Journal:  Antibiotics (Basel)       Date:  2022-07-04

5.  A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis.

Authors:  Milo Gatti; Sara Tedeschi; Filippo Trapani; Stefania Ramirez; Rita Mancini; Maddalena Giannella; Pierluigi Viale; Federico Pea
Journal:  Antibiotics (Basel)       Date:  2022-08-01

Review 6.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11

7.  Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants.

Authors:  Wan-Zhen Li; Hai-Lan Wu; Yuan-Cheng Chen; Bei-Ning Guo; Xiao-Fen Liu; Yu Wang; Ju-Fang Wu; Jing Zhang
Journal:  Ann Transl Med       Date:  2021-06

8.  Synthesis, Pharmacological and Toxicological Screening of Penicillin-Triazole Conjugates (PNTCs).

Authors:  Adarsh Sahu; Preeti Sahu; Ramkishore Agrawal
Journal:  ACS Omega       Date:  2019-10-07

Review 9.  [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].

Authors:  R Menéndez; R Cantón; A García-Caballero; J Barberán
Journal:  Rev Esp Quimioter       Date:  2019-12-04       Impact factor: 1.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.